Best Peptides for Energy? Evidence and Safety Guide

“Best peptides for energy” is a search and marketing phrase, not a recognized medical category. Fatigue, sleepiness, exercise intolerance, low motivation, reduced libido, and muscle weakness are different outcomes with different causes. Combining them under “energy” can make weak evidence look more useful than it is.

This guide compares the evidence without recommending a product, stack, injection protocol, or dose.

Short answer

• No peptide has been shown to safely and reliably treat nonspecific fatigue or low energy in the general population.
• Elamipretide is FDA-approved under accelerated approval for improving muscle strength in a narrowly defined group of people with Barth syndrome. That approval does not establish it as a general energy peptide.
• MOTS-c is biologically interesting, but human research largely measures naturally occurring MOTS-c around exercise or metabolic disease. Therapeutic outcome evidence for administered MOTS-c is not established.
• Tesamorelin and bremelanotide are approved peptide drugs for specific conditions, not fatigue, workout performance, or general wellness.
• 5-Amino-1MQ, Cardarine, and ibutamoren are not peptides. Their inclusion in peptide-store categories does not change their chemistry or evidence.
• Combining compounds does not make an unproven intervention evidence-based and can create interactions that have never been studied.

Start by defining the outcome

MedlinePlus advises that fatigue lasting for weeks or not improving with sleep, nutrition, and lower stress should be evaluated because treatment depends on the cause.

Evidence comparison

Elamipretide (SS-31): approved for one rare disease

Elamipretide, sold as Forzinity, is a mitochondria-targeting peptide. In September 2025, FDA granted accelerated approval to improve muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. Barth syndrome is a rare genetic mitochondrial disorder; this is not an approval for fatigue, athletic performance, aging, or general mitochondrial optimization.

FDA's trial snapshot describes a randomized crossover study with 12 participants at one US site plus an open-label extension. Accelerated approval requires confirmatory evidence, and FDA lists a postmarketing confirmatory trial due in 2030. The appropriate conclusion is narrow: elamipretide has a specific approved use, not a transferable “energy” effect.

MOTS-c: promising biology, missing therapeutic outcomes

MOTS-c is a mitochondrial-derived peptide involved in metabolic stress signaling. Administered MOTS-c has improved exercise capacity and metabolic outcomes in mice. Human studies have instead mostly examined circulating or muscle MOTS-c before and after exercise or in metabolic conditions.

A 2026 systematic review found only nine exercise-related studies and emphasized variation in study design and limited human evidence. It called for controlled clinical trials before treating mitochondrial-derived peptides as therapies. A registered phase 1 study tested CB4211, a MOTS-c analog, primarily for safety and pharmacokinetics; results from an analog do not prove that retail MOTS-c improves fatigue or exercise performance.

Tesamorelin: an approved drug, but not for energy

Tesamorelin is a growth hormone-releasing factor analog. Its FDA-approved indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The label states that it is not indicated for weight-loss management and that long-term cardiovascular safety has not been established.

Increasing growth hormone or IGF-1 does not automatically improve energy. Benefits and risks depend on diagnosis, baseline hormone status, metabolic health, and the exact drug studied.

Bremelanotide (PT-141): sexual desire is not general energy

Bremelanotide is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women when low desire is distressing and is not caused by another medical, psychiatric, relationship, or medication factor. Its labeling says it is not intended to improve sexual performance and does not establish an indication for men or postmenopausal women.

That evidence should not be reframed as proof of more stamina, alertness, or overall “sexual energy.” Melanotan products are different compounds and cannot inherit bremelanotide's approval or evidence.

Growth-hormone secretagogues and related peptides

Ipamorelin, GHRP-2, GHRP-6, sermorelin, and other compounds are often promoted for sleep, recovery, strength, or well-being. Raising a hormone level is a surrogate effect, not proof of improved fatigue or daily function. FDA's compounding safety review identifies route-specific immunogenicity and impurity concerns for several peptide secretagogues; it also notes glucose, cortisol, and serious-adverse-event concerns in parts of the literature.

There is no validated “energy stack” supported by trials showing that combinations of these peptides improve patient-centered outcomes without increasing risk.

DSIP, Semax, Selank, Epitalon, and related claims

These peptides have mechanistic, animal, or small-study literatures involving sleep, stress, cognition, or circadian biology. That research does not establish treatment of persistent fatigue in a broadly defined population. Changes in sleep architecture, melatonin, neurotransmitters, or an animal task should not be converted into a claim of more daytime energy without replicated human trials.

Compounds commonly mislabeled as peptides

Correct classification matters because a vendor category can obscure chemical identity, regulatory status, testing requirements, and known risks.

A safer way to evaluate an “energy” claim

1. Name the symptom. Separate fatigue from sleepiness, exercise intolerance, weakness, low mood, and low desire.
2. Look for a cause. Persistent or function-limiting fatigue deserves clinical evaluation before adding a research compound.
3. Match the evidence. The exact compound, route, population, and outcome should match the claim.
4. Check clinical importance. A statistically significant biomarker or scale change may still be too small to matter.
5. Check regulatory scope. Approval for one rare disease or endocrine condition does not validate general wellness use.
6. Separate quality from efficacy. A certificate of analysis may address identity or purity; it cannot prove that the product improves energy.

Research and sourcing pathways

Use the evidence-grading methodology before comparing claims, then open the individual profiles for MOTS-c, SS-31/elamipretide, tesamorelin, or bremelanotide.

The source availability and batch-record directory can show which compounds have commercial listings and supporting documents. Directory inclusion is not proof of effectiveness, safety, legality for a particular use, or a recommendation to purchase. The sourcing framework explains how to evaluate identity, batch records, and vendor claims separately from clinical evidence.

References

1. National Library of Medicine. Fatigue. MedlinePlus. Reviewed 2025. MedlinePlus
2. US Food and Drug Administration. FDA grants accelerated approval to first treatment for Barth syndrome. 2025. FDA
3. US Food and Drug Administration. Drug Trials Snapshot: Forzinity. 2025. FDA
4. Rahman MM, et al. Mitochondrial-derived peptides activated by physical exercise as therapeutic targets for metabolic disorders: a systematic review. 2026. PubMed
5. CohBar, Inc. A phase 1a/1b study of CB4211 in healthy non-obese subjects and subjects with nonalcoholic fatty liver disease. ClinicalTrials.gov
6. US Food and Drug Administration. Egrifta SV prescribing information. FDA label
7. US Food and Drug Administration. Vyleesi prescribing information. FDA label
8. US Food and Drug Administration. Certain bulk drug substances for use in compounding may present significant safety risks. FDA
9. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat-diet-induced obesity in mice. Biochemical Pharmacology. 2018. PubMed
10. US Food and Drug Administration. Elite Supplement Center and Elite Training Facility warning letter. 2022. FDA
11. World Anti-Doping Agency. 2026 prohibited list. WADA PDF
12. US Food and Drug Administration. Agebox iKids Growth Day Formula may be harmful due to hidden ibutamoren. 2025. FDA